Manuela Cappelletti | Immunology | Industry Impact Award

Published on by Molecular Biologist

Mrs. Manuela Cappelletti | Immunology | Industry Impact Award 

Senior lab biologist | TAKIS srl | Italy

Mrs. Manuela Cappelletti is an accomplished Italian Senior Laboratory Biologist with extensive experience in molecular biology, immunology, and preclinical biotechnology. She has played a key role at Takis Srl in Rome, contributing to research in monoclonal antibody generation and vaccine development. Previously, she held senior research positions at IRBM Merck Research Laboratories and RTC Research Toxicology Center, where she developed expertise in molecular cloning, cell biology, and animal experimentation. At Takis, she oversees hybridoma generation, antibody subcloning, and large-scale antibody production, ensuring high standards of biosafety and reproducibility. Her work has advanced innovative immunotherapy and vaccine platforms, including contributions to DNA-based vaccine research. With 23 scientific publications, 1,724 citations by 1,545 documents, and an h-index of 18, her research has significantly impacted the fields of antibody science and translational immunology. Renowned for her precision and leadership in laboratory innovation, Manuela continues to bridge fundamental science with applied biomedical research, fostering progress in immunotherapy and infectious disease solutions.

Profile: Scopus | ORCID

Featured Publications

Cappelletti, M., et al. (n.d.). Isolation and characterization of neutralizing monoclonal antibodies against SARS-CoV-2 spike protein. Antibodies (Basel). Cited by 12.

Cappelletti, M., et al. (n.d.). COVID-eVax: An electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD. Molecular Therapy, 30(4). Cited by 58.

Cappelletti, M., et al. (n.d.). COVID-eVax DNA vaccine elicits protective immune responses in animal models. bioRxiv. Cited by 72.

Cappelletti, M., et al. (n.d.). Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. Journal of Gene Medicine, 5(3). Cited by 130.

Cappelletti, M., et al. (n.d.). C/EBP beta and acute phase gene regulation in liver cells. Cell Death and Differentiation, 3(2). Cited by 45.

 

Shaghayegh Baradaran Ghavami | Autoimmune disease and Immunology | Best Researcher Award

Published on by Molecular Biologist

Dr.Shaghayegh Baradaran Ghavami | Autoimmune disease and Immunology | Best Researcher Award

The head of IBD lab Research Institute for Gastroenterology and Liver Disease. Shaheed Beheshti University of Medical Sciences. Tehran, Iran

Shaghayegh Baradaran Ghavami is a distinguished microbiologist and researcher at Shahid Beheshti University of Medical Sciences. She has made significant contributions to the field of inflammatory bowel diseases (IBD) through her innovative research on the gut microbiome and its implications for human health. With a strong academic background and numerous publications, she continues to advance our understanding of microbiology and its applications in medical science.

Profile

Google Scholar

Education 🎓

Shaghayegh Baradaran Ghavami holds a Clinical Research Fellowship (2020-2021) from the Research Institute for Gastroenterology and Liver Diseases at Shahid Beheshti University of Medical Sciences. She earned her Ph.D. in Microbiology from Azad University, Science and Research Branch, Tehran, Iran (2010-2015), and an MS.c in Microbiology (2008-2010) from Islamic Azad University North Tehran Branch. She completed her BS.c in Molecular and Cellular Microbiology at the same university (2000-2004).

Experience 💼

Shaghayegh has extensive experience in research and academia. She served as a Research Assistant (2016-2020), where she conducted and supervised various research projects. During her Ph.D. (2010-2015), she focused on “Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases.” Additionally, she worked as a tutor in the Microbiology department at Azad University, Medical Branch of Tehran (2010-2019), and observed research at Dr. Jeremy Burton Lab at Lawson Health Research Institute in Canada (2018).

Research Interests 🔬

Shaghayegh’s research interests lie in microbiology, specifically in studying the gut microbiome’s role in inflammatory bowel diseases and other gastrointestinal disorders. Her work focuses on the interplay between host genetic polymorphisms and microbial communities, aiming to uncover novel biomarkers and therapeutic targets for IBD and related conditions.

Awards 🏆

Shaghayegh has been recognized for her contributions to science, including receiving a $30,000 grant from Orchid Life Company for her IBD & COVID-19 project in May 2020. She has also been nominated for various academic awards for her groundbreaking research.

Publications 📚

  1. Kazemifard N, Farmani M, Baradaran Ghavami Sh, et al. A prediction of the CRNDE role by modulating NF-κB pathway in inflammatory bowel disease (IBD). BB Rreports. 2024 May. https://doi.org/10.1016/j.bbrep.2024.101731.
  2. Vaezi Z, Baradaran Ghavami Sh, Farmani, et al. Oral Formulation of 5-Aminosalicylic Acid-Hemoglobin Bio-Adhesive Nanoparticles Enhance Therapeutic Efficiency in Ulcerative Colitis Mice: A Preclinical Evaluation. J Pharm Sci. 2024 Apr 4. https://doi.org/10.1016/j.xphs.2024.03.028.
  3. Basiji K, Sendani AA, Baradaran Ghavami Sh, et al. The critical role of gut-brain axis microbiome in mental disorders. Metab Brain Dis. 2023. https://doi.org/10.1007/s11011-023-01248-w.
  4. Khazdouz M, Daryani NE, Cheraghpour M, Baradaran Ghavami Sh, et al. The effect of selenium supplementation on disease activity and immune-inflammatory biomarkers in patients with mild-to-moderate ulcerative colitis: a randomized, double-blind, placebo-controlled clinical trial. Eur J Nutr. 2023. https://doi.org/10.1007/s00394-023-03214-9.
  5. Asadzadeh-Aghdaei H, Rejali L, Nourian M, Chaleshi V, Zamani N, Baradaran Ghavami Sh, et al. Toll-like Receptor 7 is a novel non-invasive inflammatory genetic sensor for ulcerative colitis remission monitoring. Adv Biomed Res. 2023 Feb 25. https://doi.org/10.4103/abr.abr_24_22.
  6. Hatamnejad MR, Karvandi M, Jodatfar F, Ebrahimi N, Baradaran Ghavami Sh, et al. Evaluation of adalimumab effects on left ventricle performance by echocardiography indexes among patients with immunosuppressant refractory ulcerative colitis. Front Med. 2023. https://doi.org/10.3389/fmed.2022.1008711.
  7. Hatamnejad MR, Baradaran Ghavami Sh, Marzieh Shirvani, et al. Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.980189.
  8. Kazemifard N, Dehkohneh A, Baradaran Ghavami Sh. Probiotics and probiotic-based vaccines: A novel approach for improving vaccine efficacy. Front Med. 2022. https://doi.org/10.3389/fmed.2022.940454.
  9. Rajabnia M, Hajimirzaei SM, Hatamnejad MR, Baradaran Ghavami Sh, et al. Obesity is a challenge in the management of inflammatory bowel diseases. Immunol Res. 2022. https://doi.org/10.1007/s12026-022-09315-7.
  10. Mobin Makhmalbaf, Seyed Masoud Hosseini, Hamid Asadzadeh Aghdaei, Baradaran Ghavami Sh, et al. Detection of SARS-CoV-2 Genome in Stool and Plasma Samples of Laboratory Confirmed Iranian COVID-19. Front Mol Biosci. 2022. https://doi.org/10.3389/fmolb.2022.865129.
  11. Khoramjoo SM, Kazemifard N, Baradaran Ghavami Sh, Farmani M, Shahrokh S, Asadzadeh Aghdaei H, Sherkat G, Zali MR. Overview of Three Proliferation Pathways (Wnt, Notch, and Hippo) in Intestine and Immune System and Their Role in Inflammatory Bowel Diseases (IBDs). Front Med (Lausanne). 2022. https://doi.org/10.3389/fmed.2022.865131.